Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 07 Jun 2024 00:29:52 +0200Fri, 08 Mar 2024 16:02:00 +0100Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0421/2019https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip04-17-m01Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0421/2019https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip04-17-m01Fri, 08 Mar 2024 16:02:00 +0100Human medicineHuman medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Date of authorisation: 21/10/2014, Revision: 33, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imbruvicaHuman medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Date of authorisation: 21/10/2014, Revision: 33, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imbruvicaThu, 07 Mar 2024 15:44:00 +0100Human medicineImbruvica : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-3791-steps-after_en_0.pdfImbruvica : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-3791-steps-after_en_0.pdfThu, 07 Mar 2024 11:10:00 +0100Human medicine